What Vedanta Biosciences does

Vedanta Biosciences is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, developing Live Biotherapeutic Products (LBPs) composed of defined bacterial consortia for serious gastrointestinal diseases. The company's lead asset, VE303, is an orally administered eight-strain consortium of live commensal bacteria currently in a pivotal Phase 3 trial (RESTORATiVE303) for prevention of recurrent Clostridioides difficile infection (CDI). The pipeline additionally includes VE202, a 16-strain consortium for ulcerative colitis (Phase 2 did not meet primary endpoint in August 2025), and VE707, a preclinical program targeting Gram-negative antimicrobial-resistant infections with IND submission planned for the first half of 2026.

The company's proprietary Product Engine spans a strain library of approximately 100,000 bacterial isolates drawn from four continents, computational consortium design tools, and in-house CGMP manufacturing capabilities covering 75 bacterial species. Vedanta holds an exclusive license to the foundational Honda patents covering Clostridium clusters IV and XIVa from the University of Tokyo, with an IP estate exceeding 80 issued patents and pending applications extending coverage to 2043. The European Patent Office fully upheld three core Honda patents in 2023.

Vedanta's business model is standard for late clinical-stage biopharma: pre-revenue with no approved products, generating economic value through eventual pharmaceutical product sales contingent on regulatory approval. Revenue is supplemented by substantial non-dilutive government funding, including a BARDA contract of up to $114.2 million for VE303 development and CARB-X grants of approximately $16.6 million. The company employs 101-250 staff, is privately held with institutional and strategic backers including Magnetar Capital, Pfizer, AMR Action Fund, and AXA Investment Managers, and is preparing commercial infrastructure under a newly appointed Head of Commercial.

Name

Vedanta Biosciences

Legal name

Vedanta Biosciences, Inc.

Website

https://vedantabio.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

Vedanta Biosciences is a clinical-stage biopharmaceutical company developing orally administered defined bacterial consortia (Live Biotherapeutic Products) for serious gastrointestinal diseases, with lead asset VE303 in pivotal Phase 3 for recurrent C. difficile infection.

Ownership category

akta.pro rank

Product category

Microbiome Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Live Biotherapeutic Products (LBPs) (HLAAAFAA)

akta.pro secondary industries

Consortia & Defined Microbial Community Therapeutics (HLAAAFAC), Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)

Keywords

• Microbiome therapeutics
• Live biotherapeutic products
• Bacterial consortia therapy
• Gastrointestinal disease drugs
• Biologics manufacturing

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Developing Live Biotherapeutic Products (LBPs) for gastrointestinal diseases. VE303 is in Phase 3 registrational trial for prevention of recurrent C. difficile infection. Potential future revenue from pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Vedanta Biosciences develops and manufactures oral Live Biotherapeutic Products (LBPs) consisting of rationally designed defined bacterial consortia to treat gastrointestinal diseases. Its lead candidate VE303 is an eight-strain commensal bacterial consortium in pivotal Phase 3 development for the prevention of recurrent C. difficile infection. The company also develops VE202 for ulcerative colitis and VE707 for Gram-negative antimicrobial-resistant infections, supported by a proprietary product engine and in-house CGMP manufacturing.

Product overview

Vedanta Biosciences is developing a portfolio of defined bacterial consortia as oral Live Biotherapeutic Products (LBPs) for gastrointestinal diseases. The company's lead product is VE303, an eight-strain defined bacterial consortium in pivotal Phase 3 for prevention of recurrent C. difficile infection. VE202 (16-strain consortium for ulcerative colitis) completed Phase 2 but did not meet primary endpoint. VE707 is a preclinical program for Gram-negative AMR infections. The company's proprietary Product Engine platform enables rational selection and manufacturing of defined bacterial consortia from pure clonal cell banks, supported by in-house CGMP manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• VE303 VE303 is an orally-administered defined bacterial consortium candidate consisting of eight strains of live commensal bacteria developed for the prevention of recurrent C. difficile infection (rCDI). It is manufactured from pure clonal cell banks yielding a standardized pharmaceutical composition that bypasses the need for donor fecal material. VE303 is currently in pivotal Phase 3 (RESTORATiVE303) and holds FDA Orphan Drug and Fast Track designations.
• VE202 VE202 is a defined bacterial consortium of 16 non-pathogenic, non-toxigenic Clostridia strains developed as an oral therapy for inflammatory bowel disease, specifically mild-to-moderate ulcerative colitis. The Phase 2 COLLECTiVE202 study did not meet its primary endpoint in August 2025.
• VE707 VE707 is a preclinical defined bacterial consortium candidate designed to prevent Gram-negative antimicrobial-resistant (AMR) infections, including carbapenem-resistant and ESBL-producing Klebsiella pneumoniae and Escherichia coli, by reducing gut colonization with multidrug-resistant organisms in high-risk populations. IND submission is planned for 1H 2026.
• Product Engine The Product Engine is Vedanta's proprietary discovery platform integrating one of the world's largest libraries of gut bacteria strains (nearly 100,000 isolates from hundreds of individuals across four continents), vast clinical datasets, proprietary computational consortium design tools, co-culture systems, and animal models. It supports rational selection and development of defined bacterial consortia as Live Biotherapeutic Products.

Quantifiable outcome

• VE303 reduced CDI recurrence rate to 13.8% vs 45.5% for placebo (31.7% absolute risk reduction, >80% reduction in odds of recurrence) in Phase 2 CONSORTiUM study
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• University of TokyocoreStrategic or Co-development PartnerHonda patents are exclusively licensed to Vedanta from the University of Tokyo. These fundamental patents cover compositions and therapeutic uses of clostridial bacteria derived from the human microbiome. Dr. Kenya Honda, inventor, is a scientific co-founder of Vedanta.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Seres Therapeutics: Developed Vowst (SER-109), the first FDA-approved oral microbiome therapeutic for recurrent C. difficile infection. Directly comparable as a defined-consortium LBP competitor pursuing the same rCDI indication with an oral spore-based product.
• Ferring Pharmaceuticals (Rebyota): Markets Rebyota (fecal microbiota, live-jslm), the first FDA-approved microbiome therapy for rCDI. Direct competitor in the recurrent CDI space, though Rebyota is rectally administered rather than oral.
• Finch Therapeutics: Developed CP101, an oral microbiome therapeutic for recurrent C. difficile infection. Directly comparable microbiome platform pursuing the same rCDI indication, though Finch has scaled back operations.
• Assembly Biosciences: Clinical-stage biotech developing microbiome-based therapies for serious diseases, including CDI and inflammatory conditions. Comparable as a platform LBP company with multiple defined-consortium programs.
• MaaT Pharma: European clinical-stage company developing microbiome-based therapies (MaaT013, MaaT033) for GI diseases including CDI and acute Graft-versus-Host Disease. Direct microbiome peer operating in the same indication space.
• Rebiotix (Ferring subsidiary): Pioneer in standardized FMT-based therapeutics, acquired by Ferring. Developed Rebyota, the first FDA-approved microbiome product, making it the closest historical comparator to Vedanta's LBP approach.
• 4D pharma: UK-based clinical-stage microbiome therapeutics company developing single-strain and defined-consortium LBPs (e.g., Blautix for IBS). Comparable as a live biotherapeutic platform pursuing GI indications.

Emerging players

• Second Genome: Clinical-stage biotech identifying microbiome-derived therapeutics for GI and metabolic diseases. Comparable microbiome discovery platform, though focused more on small-molecule drugs derived from microbiome insights than whole-consortium LBPs.
• Eligo Bioscience: Developer of engineered phage-based microbiome medicines (Eligobiotics). Comparable as a microbiome-focused therapeutics platform, though uses a different modality (phage-delivered payloads rather than whole consortia).

Broad incumbents

• Pfizer (CDI/AMR franchise): Major pharmaceutical investor in Vedanta with a broad infectious disease and CDI portfolio (historically Dificid). Comparable as a strategic counterparty and potential acquirer with overlapping interest in the rCDI market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/vedantabio
• LinkedInlinkedin.com/company/vedanta-biosciences-inc-
• Facebookfacebook.com/profile.php

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds18 records

Investors43 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vedanta Biosciences